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The initial interaction of human cytomegalovirus with fibroblasts
triggers, and then partially blocks, an innate immune response path-
way that leads to the induction of IFN-responsive genes and proin-
flammatory chemokines. Infection of fibroblasts with human cyto-
megalovirus inhibited their ability to respond to exogenous IFN.
Consistent with the observation that the block did not depend on de
novo viral protein synthesis, ectopic expression of the viral UL83-
coded pp65, an abundant virion protein, inhibited IFN signaling.
Furthermore, DNA array analysis showed that infection with a pp65-
deficient mutant virus caused a much stronger induction of many
IFN-response and proinflammatory chemokine RNAs than infection
with wild-type virus. The nuclear DNA-binding activities of transcrip-
tion factors NF-B and IRF1 were induced to a much greater extent
after infection with the pp65-deficient mutant than with wild-type
virus. IFN-stimulated gene factor 3 DNA-binding was modestly en-
hanced, whereas IRF3 activity was not affected by mutation of pp65.
Together, these results imply that pp65, which is delivered to newly
infected cells in the virion, antagonizes a pathway that affects NF-B
and IRF1 and prevents the accumulation of mRNAs encoded by
numerous cellular antiviral genes.
Human cytomegalovirus (HCMV) is a ubiquitous -herpesvirus, and is a significant cause of disease for unborn children
and immuno-compromised patients. Infections begin at mucosal
epithelial surfaces before spreading to a variety of other cell-types
and tissues. HCMV infection provokes a potent T cell response that
suppresses the infection, but, like other herpesviruses, a lifelong
latent infection is established after the primary infection is cleared.
Latent virus is found in monocytes and CD34 hematopoietic stem
cells (1–3). HCMV executes multiple immune-evasive activities in
infected cells. The viral proteins US2, US3, US6, and US11
cooperate to inhibit MHC-I presentation of viral peptides to CD8
T cells (4, 5). The secreted HCMV protein UL21.5 acts as a soluble
decoy receptor for the proinflammatory chemokine RANTES (D.
Wang, W. Bresnahan, and T.S., unpublished data), and HCMV
expresses a viral homologue of IL-10, an antiinflammatory inter-
leukin (6).
A key component of the innate-immune response to viral infec-
tions is the IFN pathway. IFNs are cytokines that are synthesized
in response to virus infection. They bind to their cognate receptors
on target cells and activate a signaling pathway that coordinately
induces a set of IFN-responsive genes, many of which exhibit
antiviral activity. Fibroblasts, which are commonly used to study
HCMV replication, produce primarily IFN-. HCMV infection
triggers the accumulation of many IFN-responsive mRNAs (7–10).
However, we have previously shown that a substantially greater
number of IFN-responsive genes are induced at 6 h after infection
with HCMV particles that were inactivated by UV treatment before
infection than with replication-competent virus (10). This implies
that, immediately after infection, HCMV synthesizes a gene prod-
uct that suppresses the up-regulation of IFN-responsive genes.
However, UV-inactivation of viral particles did not lead to full
activation of the IFN pathway, possibly indicating that another
block is instituted that is independent of de novo HCMV gene
expression in newly infected cells.
Here we demonstrate that the abundant HCMV virion protein,
pp65, blocks the induction of some, but not all, IFN-responsive
genes by inhibiting an innate immune response pathway that leads
to the activation of NF-B and IRF1.
Materials and Methods
Cells, Viruses, and Reagents. Primary human foreskin fibroblasts at
passage 9–17 were maintained in medium supplemented with 10%
FCS. A plaque-purified derivative of the AD169 strain of HCMV,
originally obtained from the American Type Culture Collection,
was used as the wild-type virus in these studies. The pp65-deficient
mutant, HCMVpp65, contained the bacterial neomycin phospho-
transferase gene in place of the AD169 UL83 ORF (11). Virus
particles were partially purified from cell culture medium by
centrifugation through a sorbitol cushion and resuspended in PBS,
stored as virus stocks at 80°C, and stocks were titered by plaque
assay on human fibroblasts. In all experiments, fibroblasts were
infected at a multiplicity of 5 plaque-forming units per cell for 1 h
before conditioned medium was added back to the dish.
Recombinant IFN- was from Calbiochem, and all antibodies
were obtained from Santa Cruz Biotechnology except antibody
to p-stat1 (Cell Signaling Technology) and p-stat2 (Upstate
Biotechnology).
DNA Array Analysis. Infected fibroblasts were suspended in TRIzol
and then stored at 80°C until they were processed by purification
of total RNA. A total of 5 g of each RNA sample was used as a
template for cDNA synthesis in a reaction that was primed with an
oligonucleotide containing an oligo(dT) stretch and a T7 RNA
polymerase promoter. The cDNA was used to make biotin-labeled
cRNA probes with an RNA transcript labeling kit (Enzo Diagnos-
tics). The cRNA was purified to remove unincorporated ribonucle-
otides, and 15 g was fragmented at 95°C for 30 min in buffer
containing 40 mM Tris-acetate (pH 8.1), 100 mM KOAc, and 30
mM KOAc. The fragmented cRNA was hybridized to HG-U95Av2
arrays for 16 h at 45°C. The arrays were washed and stained as
described by using the Affymetrix antibody amplification protocol
(12). Scanning was performed by using an Agilent gene chip
scanner. Scanned chip data sets were analyzed by using Affymetrix
GeneChip analysis software. The ‘‘fold change’’ in intensity for the
probe set was averaged for two replicate experiments.
Electrophoretic Mobility Shift Assay (EMSA). Nuclear extracts were
prepared and used for EMSAs following the protocol described
previously (13). The sequences for the oligonucleotides used as
probes are as follow (5–3): IFN-stimulated response element
(ISRE) (sense), GATCGGGAAAGGGAAACCGAAACTG-
AAGCCA; ISRE (antisense), TGGCTTCAGTTTCGGTTTC-
Abbreviations: HCMV, human cytomegalovirus; Stat, signal transducer and activator of
transcription; ISRE, IFN-stimulated response element; DAPI, 4,6-diamidino-2-phenylin-
dole; ISGF3, IFN-stimulated gene factor 3.
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CCTTTCCCGATC; NF-B (sense), AGTTGAGGGGACTTT-
CCCAGGC; NF-B (antisense), GCCTGGGAAAGTCCCC-
TCAACT; NF-B (mutant sense), AGTTGAGGCGACTTTC-
CCAGG; NF-B (mutant antisense), GCCTGGGAAAGT-
CGCCTCAACT. A total of 5 g of nuclear protein was used per
binding reaction.
Immunofluorescence. Fibroblasts growing on glass coverslips were
processed for immunofluorescence at room temperature. Cells
were washed with PBS, fixed with 2% paraformaldehyde for 15 min,
washed again, permeabilized with 0.1% Triton X-100, and blocked
with 2% BSA in PBS containing 0.05% Tween 20 for 60 min. Cells
were next incubated with primary antibody (diluted 1:40 in blocking
buffer) for 60 min, and then with fluorescently labeled secondary
anti-mouse or anti-rabbit antibody (1:1,000 dilution in blocking
buffer) plus 1 gml 4,6-diamidino-2-phenylindole (DAPI) for 60
min. The coverslips were then washed and mounted on a slide with
17 l of SlowFade (Molecular Probes) before being analyzed by
confocal microscopy.
Results
HCMV Blocks the Ability of Infected Cells to Respond to Exogenously
Added IFN. To investigate how HCMV infection affects the IFN
response pathway, we treated fibroblasts with IFN- at 4 h after
mock infection or infection with wild-type virus. The cells were
harvested 2 h later, RNA was prepared and tested for the induction
of the MxA IFN-responsive gene (Fig. 1A Left). The level of MxA
RNA was consistently lower in infected than in mock-infected
fibrobasts, implying that HCMV infection antagonizes the IFN
response pathway. The block to IFN signaling was even more
apparent when the experiment was carried out in the presence of
cycloheximide (Fig. 1A Right). This finding indicates that the ability
of HCMV to block the induction of MxA RNA does not depend on
de novo viral protein synthesis and that a structural component of
the virus particle is responsible. The finding that the block is more
pronounced in the presence of cycloheximide is likely due to the fact
that the drug prevents the production of IFN, blocking its ability to
contribute to the induction of MxA RNA. Curiously, the MxA RNA
appears as a doublet in the presence of cycloheximide. The doublet
was consistently observed in multiple experiments, and the reason
for the generation of two bands is unclear.
Treatment of cells with IFN- or - results in activation of the
Janus kinase 1 (Jak1) and Tyk2 kinases, which promote the
phosphorylation of the signal transducer and activator of transcrip-
tion (Stat)1 and -2 proteins. The phosphorylated Stat proteins then
form a heterodimeric complex that translocates to the nucleus and
associates with p48 to form the IFN-stimulated gene factor 3
(ISGF3) complex. This transcription factor up-regulates the ex-
pression of IFN-response genes by binding to the ISRE promoter
Fig. 1. HCMV blocks IFN signaling. (A) Untreated fibroblasts (Left) or fibroblasts
continuously treated with 100 gml cycloheximide beginning 1 h before infec-
tion (Right) were mock-infected or infected with wild-type HCMV. At 4 h after
infection, IFN- (2,000 unitsml) was added to the cultures, and at 6 h after
infection, RNA was harvested and assayed for the IFN-sensitive gene MxA by
Northernblot.The levelof28SribosomalRNA(rRNA)wasmonitoredbyethidium
bromide fluorescence as a loading control. (B) Fibroblasts were pretreated with
100 gml cycloheximide beginning 1 h before mock-infection or infection with
wild-type HCMV. At 4 h after infection, 2,000 unitsml IFN- was added to
infected and mock-infected cells. At 6 h after infection, cells were lysed and
extracts were analyzed by Western blot assay for the indicated proteins by using
specific antibodies. Stat1 and Stat2 designate total Stat protein; p-Stat1 and
p-Stat2 designate phosphorylated Stat proteins.
Fig. 2. IFN- signaling is antagonized by pp65. (A) Fibroblasts were infected
with recombinant adenoviruses expressing hemagglutinin (HA)-tagged pp65
(Ad-pp65), HA-tagged pp71 (Ad-pp71), or GFP (Ad-GFP) at a multiplicity of 104
particles per cell. At 24 h after infection, 2,000 unitsml IFN- was added for
1 h. RNA was then prepared, and the level of MxA mRNA was assayed by
Northern blot (Upper). Protein samples also were assayed by using an anti-
body specific for the HA epitope (-HA) (Lower) to confirm the expression of
pp65 and pp71. (B) Fibroblasts were infected with wild-type HCMV or a
pp65-deficient mutant (pp65). After 6 h, cells were harvested and RNA was
extracted and analyzed by Northern blot using 32P-labeled probes specific for
the indicated IFN-responsive genes.




















element (14, 15). It has previously been reported that HCMV
infection blocks IFN signaling at much later times after infection
(24–48 h) than we have observed here, and that this block corre-
lates with loss of Jak1 and p48 (16). Western blot analyses (Fig. 1B)
demonstrated that the levels of Jak1, Stat1, Stat2, and p48 were not
affected by HCMV at 6 h after infection, when the virus has clearly
blocked the induction of MxA RNA. HCMV infection induced
Stat1 phosphorylation to the same extent as treatment with IFN-.
Little Stat-2 phosphorylation was caused by HCMV infection in the
presence of cycloheximide, although Stat-2 phosphorylation could
still be strongly induced in infected cells by the addition of IFN-.
We therefore conclude that HCMV prevents the infected cell from
inducing MxA RNA in response to exogenously added IFN at 6 h
after infection by a mechanism other than the failure to phosphor-
ylate Stat proteins or to modulate Jak1 or p48 levels.
IFN- Signaling Is Blocked by pp65. To search for a virion component
that can block the induction of MxA RNA in response to IFN, we
initially tested the activity of pp65 and pp71, two abundant virus-
coded proteins that are packaged into the tegument domain of the
HCMV particle. We infected fibroblasts with recombinant adeno-
viruses that lack the adenovirus E1A gene and express either pp65,
pp71, or GFP. At 24 h after infection, we added IFN- to infected
cells for 1 h and monitored the induction of MxA RNA by Northern
blot assay (Fig. 2A). Cells expressing pp65 accumulated much less
MxA RNA than cells expressing pp71 or GFP, indicating that pp65
can block elements of the IFN signaling pathway. To confirm and
extend this result, the accumulation of RNAs encoded by several
additional IFN-responsive genes was monitored by Northern blot
assay after infection with wild-type HCMV or a mutant (pp65)
lacking the UL83 ORF, which codes for pp65 (Fig. 2B). At 6 h after




IFN--inducible early response gene 6.5  2.2 589.6  57.7 90.8
IFN- treatment inducible mRNA 0.7  0.1 26  0 37.2
IFN--2 3.2  0.8 111.5  0 34.9
Cig5 35.7  5.3 461.8  22.2 13
Monocyte chemotactic protein 2 1.5  0.3 14  0 9.4
Guanylate binding protein isoform I (GBP-2) 3.2  0.5 28.9  1.5 9.1
GTP cyclohydrolase I 6.8  3.5 60.3  11.8 8.9
IFN--inducible indoleamine 2,3-dioxygenase 2.6  0.7 22.7  2.3 8.8
1.6-kb mRNA for 2–5A synthetase induced by IFN 14.5  2.2 102  24.8 7.1
2–5 oligoadenylate synthetase 59 kDa 20.7  5.1 115.5  5.7 5.6
Human p78 protein 9.4  4.0 48.6  0 5.2
Hepatitis C-associated microtubular aggregate protein p44 2.7  0.6 11.8  0.6 4.4
IFN-inducible 2 protein 1.9  0.1 8.3  0.5 4.4
MxB 2.4  0.2 9.6  0.5 4
IFN regulatory factor 1 1.6  0.3 5.7  0.6 3.6
Oligo(A) synthetase E gene 8.6  0 28.9  1.5 3.4
Homo sapiens cDNA, 5 end/clone  IMAGE-446622 11.6  3.4 36.8  0 3.2
RING4 1.9  0.1 5.5  0.3 2.9
X87344: H. sapiens DMA, DMB, HLA-Z1, IPP2, LMP2, TAP1 1.2  0.1 3.4  0.2 2.9
H. sapiens mRNA; cDNA DKFZp586E0518 1.4  0.2 3.9  0.2 2.8
H. sapiens mRNA expressed in osteoblast 1.8  0.8 4.8  0.3 2.7
69-kDa 25 oligoadenylate synthetase 1.4  0.1 3.2  0.5 2.3
IFN--inducible protein (IP-30) 1.5  0 3.4  0.2 2.3
Cig49 48.7  4.8 104  0 2.2
Human nuclear phosphoprotein mRNA 3.6  1.6 7.7  2.3 2.2
71-kDa 25 oligoadenylate synthetase 2.5  0.6 5.2  0.8 2.1
ISG-54K 148.5  29 304.7  15 2.1
DNA sequence from clone 494G10 on chromosome 22 2  0.8 3.3  0.4 1.7
IFN-inducible protein (AIM2) 2.8  1.1 4.2  0.7 1.5
ICB-1 10.3  0.5 12.3  2.4 1.2
pp65 suppresses expression of IFN-response genes in HCMV-infected cells. DNA array analysis was carried out on
duplicate samples of RNA prepared from fibroblasts 6 h after infection with wild-type HCMV or pp65. The fold
changes for the genes shown were averaged, and the standard deviation was calculated. The ‘‘Ratio’’ column is the
average fold up-regulation in response to pp65 divided by the average fold up-regulation in response to wild-type
HCMV.
Fig. 3. Globaleffectofpp65oncellulargeneexpression.DNAarrayanalysiswas
carried out on duplicate samples of RNA prepared from fibroblasts at 6 h after
infection with wild-type HCMV or pp65. (A) The total number of RNAs up- or
down-regulatedbyafactorof 3 intworeplicateswasdeterminedandgraphed.
(B) The number of RNAs induced by a factor 3 in both replicates, which were
previously shown to be induced by IFN (10), was determined and graphed.



























infection, some RNAs (IFN-, MxA, ISG-15K) were more strongly
induced by pp65 than by wild-type HCMV, indicating that pp65
inhibits their induction in HCMV-infected cells. Other IFN re-
sponse genes (cig1, cig49), however, showed little difference in their
response to the two viruses. This finding implies that pp65 plays a
role in suppressing a distinct subset of IFN response genes. This
result is reminiscent of the finding that UV inactivation of the virus
particles leads to a much stronger induction of some IFN-responsive
genes than others (10).
Global Effect of pp65 on Cellular Gene Expression. We next examined
the effect of pp65 on the accumulation of a larger set of cellular
RNAs. Fibroblasts were infected with wild-type HCMV or pp65
for 6 h, and cellular RNA levels were analyzed by using the
Affymetrix HG-U95A array that monitors 12,600 cellular tran-
scripts. As shown in Fig. 3A, at this time after infection, wild-type
HCMV altered the level of 117 cellular RNAs by a factor of 3 (43
up-regulated and 74 down-regulated), whereas the pp65-deficient
mutant altered the expression of 246 cellular RNAs (179 up-
regulated and 67 down-regulated). This result demonstrates that
pp65 is required to suppress the induction of numerous cellular
RNAs early in infection.
Many cellular RNAs (n  180) were elevated to a greater extent
(2-fold) in response to pp65 than to the wild-type virus. This
group of RNAs included many known IFN-responsive genes (Table
1) and proinflammatory chemokines (Table 2), including IFN-
itself. We previously defined a set of 79 genes that are induced by
a factor of 3 by treatment of fibroblasts with IFN- (10). The
pp65-deficient mutant up-regulated 29 of these IFN response genes
by a factor of 3 at 6 h after infection. By contrast, wild-type
HCMV infection induced only 11 of these genes at 6 h after
infection (Fig. 3B). The extent to which IFN-responsive RNAs were
induced by pp65 relative to wild-type HCMV varied significantly
from gene to gene, ranging from 1.2- to 90-fold. This is consistent
with the Northern blot assay displayed in Fig. 2B. The selective
nature of pp65 action suggests that it targets a component of the
IFN response pathway that is important for the regulation of a
subset of responsive genes, but not for the pathway as a whole.
pp65 Inhibits IRF1 and NF-B Activity in HCMV-Infected Cells. As noted
above, IFN- and  responsive genes can be induced by the binding
of ISGF3 (a complex of Stat1, Stat2, and p48) to ISRE sequences
in their transcriptional regulatory regions. During infection with
viruses, a number of other factors, such as IRF1 and IRF3, also can
bind to ISREs and regulate transcription (17, 18). Furthermore,
NF-B participates in the activation of many IFN response genes
and proinflammatory chemokine genes (19, 20). To determine
whether pp65 was functioning by targeting any of these factors, we
analyzed their activities at 6 h after infection with pp65 as
compared with wild-type virus. DNA-binding activities were mea-
sured by EMSA, protein levels were assayed by Western blot, and
protein locations were determined by immunofluorescence.
Three distinct complexes were produced when nuclear extracts
from infected cells were incubated with a 32P-labeled ISRE (Fig. 4A
Left). Their relative sizes, as well as supershift assays performed
with antibodies that recognize factors known to bind to ISREs,
identified the complexes as IRF1, IRF3, and ISGF3 (Fig. 4A Right).
Infection with the pp65 mutant consistently caused a slightly
stronger (2-fold) recruitment of ISGF3 to the ISRE than did
infection with wild-type HCMV (Fig. 4A Left), suggesting that pp65
might exert a mild inhibitory effect on the DNA-binding activity of
this transcription factor. A Western blot assay showed that the levels
of Stat1 and Stat2 phoshorylation were equivalent after infection
with mutant or wild-type virus (Fig. 5), and an immunofluorescence
assay showed that the two Stat proteins were relocated to the
nucleus by 6 h after infection with either virus (Fig. 6). We conclude
that pp65 does not inhibit antiviral gene expression by preventing
Stat12 phosphorylation or nuclear translocation, and it seems
unlikely that the modest difference in ISGF3 binding could explain
the dramatic increases in expression levels for some IFN response




Chemokine exodus-1 0.3  0.9 23  9.8 76.7
RANTES 1.5  0.5 76.2  3.8 50.8
GRO- 2.3  1.1 48  22.7 20.9
Chemokine  3 0.9  0.3 11  1.7 12.3
Monocyte chemotactic protein 2 1.5  0.3 14  0 9.4
Monocyte chemotactic protein 3 0.9  0.5 6.8  0.4 7.6
GRO- 0.8  0.9 4.2  0.7 5.3
IL-1- 2.9  0.3 8.2  2.4 2.9
Mig 3.7  0.4 10.7  2.1 2.9
pp65 suppresses expression of proinflammatory chemokines in HCMV in-
fected cells. DNA array analysis was carried out on duplicate samples of RNA
prepared from fibroblasts at 6 h after infection with wild-type HCMV or pp65.
The fold changes for the genes shown were averaged and the standard deviation
calculated. The ‘‘Ratio’’ column is the average fold up-regulation in response to
pp65 divided by the average fold up-regulation in response to wild-type HCMV.
Fig. 4. The activation of IRF1 and NF-B is inhibited by pp65. Fibroblasts were
infected with wild-type HCMV or pp65, and nuclear protein extracts were
prepared6h later.Theextractswere incubatedwith 32P-labeledoligonucleotides
containing an ISRE motif (A Left) or an NF-B-binding site (B Left) and resolved on
a nondenaturing polyacrylamide gel. To confirm the identity of the complexes
binding the ISRE, supershift assays were performed on a pp65-infected nuclear
extract by using antibodies to the indicated polypeptide constituents of ISRE-
binding activities (A Right). To confirm the identity of the complex binding the
NF-B probe, a competition assay was carried out (B Right). Nuclear extracts from
cells treated with tumor necrosis factor  were incubated with the 32P-labeled
NF-B binding site probe plus either an unlabeled competitor DNA with the
wild-type motif or a motif with a mutation that abolishes NF-B binding.




















genes seen in pp65 as compared with wild-type infections (Tables
1 and 2).
Recruitment of IRF3 in nuclear extracts to the ISRE was not
greater after infection with pp65 than with wild-type virus (Fig.
4A), indicating that pp65 does not inhibit this factor’s DNA-binding
activity. Furthermore, Western blot (Fig. 5) and immunofluores-
cent (Fig. 6) assays on infected cells showed that a similar amount
of IRF3 relocated to the nuclear compartment after infection with
HCMV or pp65.
IRF1 binding to the IRSE was substantially enhanced in nuclear
extracts prepared after infection with the pp65 mutant as com-
pared with wild-type virus (Fig. 4A). Furthermore, the amount of
IRF1 protein was markedly induced after infection with pp65 as
compared with wild-type virus, and, correspondingly, IRF1 accu-
mulation in nuclear extracts was greater for pp65 (Fig. 5). Im-
munolocalization showed accumulation of IRF1 in the nucleus for
both viruses (Fig. 6), but the difference in protein levels for the two
viruses that was evident in the Western blot assay was not as
apparent in their fluorescent intensities.
Finally, we examined NF-B activity in pp65 versus wild-type
virus-infected cells. Previous studies have shown that HCMV
infection rapidly activates NF-B (21, 22). Consistent with these
reports, at 6 h after infection we observed the formation of a
complex that shifted a 32P-labeled oligonucleotide containing a
NF-B binding site probe (Fig. 4B Left). Tumor necrosis factor ,
a known activator of NF-B, induced the formation of a complex
that exhibited identical migration, and the identity of the complex
was further confirmed by performing a competition assay with
unlabeled oligonucleotides that either corresponded to the labeled
probe or contain a mutation that abolishes NF-B binding (Fig. 4B
Right). Strikingly, the level of NF-B DNA-binding activity was
much greater in nuclear extracts from cells infected with pp65 as
compared with its wild-type parent (Fig. 4B Left), indicating that
pp65 has a strong inhibitory effect on the activation of NF-B in
infected cells. A Western blot assay demonstrated that the total
level of the NF-B p65 subunit was not altered by infection with
either virus, but the mutant caused a more substantial relocation of
NF-B p65 to the nuclear compartment than did the wild-type virus
(Fig. 5). An immunolocalization assay confirmed this result (Fig. 6).
Discussion
The importance of the IFN system in controlling viral infection is
attested to by the many diverse mechanisms that viruses have
evolved to antagonize it. For example, the adenovirus E1A protein
inhibits IFN signaling (23) and the adenovirus virus-associated
RNAs block activity of the IFN-inducible protein kinase R (PKR)
(24), myxoma virus expresses a soluble decoy IFN- receptor (25),
and the vaccinia virus E3L protein blocks the activity of PKR as well
as the unidentified kinase that phosphorylates IRF3 (26). Among
the herpes viruses, the Epstein–Barr virus EBNA-2 protein blocks
IFN signal transduction (27) and the EBER RNAs inhibit activa-
tion of PKR (28). Two herpes simplex virus type 1 proteins, ICP0
and 34.5, target distinct aspects of the IFN pathway. ICP0 coun-
teracts a block to viral transcription, whereas 34.5 targets a block
to translation (29, 30).
We have previously shown that HCMV infection induces the
58-kDa DNAJ-C3 protein, a natural inhibitor of PKR, presumably
to avoid the antiviral effects of this kinase (10). We also speculated
that in the first few hours of infection, HCMV synthesizes a protein
that suppresses the induction of IFN-responsive genes, because the
block is partially relieved when cells are infected with UV-
inactivated virus that is unable to express proteins from its genome
(10). Here we show that, in addition to the block mediated by a
newly expressed viral protein, HCMV delivers a virion protein to
cells that antagonizes the induction of a subset of IFN-responsive
genes (Fig. 1).
Fig. 5. Western blot assays of factors known to regulate IFN-responsive
genes. Fibroblasts were infected with wild-type HCMV or pp65. At 6 h after
infection, cells were lysed and extracts of total cell protein (Left) and nuclear
protein (Right) were prepared. The protein samples were then analyzed by
Western blot assays using antibodies specific for the indicated proteins.
Fig. 6. Immunofluorescent localization of factors known to regulate IFN-
responsive genes. Fibroblasts grown on coverslips were infected with wild-
type HCMV or pp65. At 6 h after infection, the cells were fixed, permeabil-
ized, and stained with antibodies to the proteins indicated (red). Nuclei were
stained with DAPI (blue).



























UL83-coded pp65 interferes with IFN signaling in cells where it
is expressed (Fig. 2A) and it is required to suppress the expression
of IFN-responsive genes in HCMV-infected cells (Fig. 2B). DNA
array analysis showed that, in the absence of pp65, HCMV infection
more strongly induced the accumulation of many RNAs encoded by
IFN responsive genes (Table 1) and proinflammatory chemokine
genes (Table 2). These data argue that pp65, which rapidly moves
to the nucleus after it is delivered to infected cells as a virion
component (7, 31), suppresses antiviral cellular gene expression at
the start of infection.
It is notable that the effect of deleting pp65 from the viral
genome, with respect to changes in the expression of IFN-response
genes (Tables 1 and 2), is similar to that resulting from UV-
inactivation of the viral particle (10). However, pp65 is not likely the
target of UV-inactivation. First, there are several differences in the
profiles of IFN-responsive genes induced by the two conditions. For
example, IFN-inducible peptide 6–16 and toll-like receptor 3 are
induced by UV-treated virus but not pp65-deficient virus, whereas
IFN- treatment inducible protein is induced by pp65-deficient
virus but not by UV-inactivated virus. Second, there are many
differences in the effects of the UV-inactivated virus as compared
with the pp65-deficient virus on the accumulation of non-IFN-
responsive RNAs. Third, pp65 is not significantly expressed from
the viral genome at 6 h after infection when its effect has been
observed. It is conceivable that pp65 protein function is damaged
or altered by UV treatment of virions. However, we favor the
interpretation that a second, as yet unidentified, viral protein that
is expressed de novo from the viral genome after infection also
inhibits antiviral gene expression. Expression of this protein would
be blocked by UV treatment. Presumably, the de novo-expressed
viral protein and pp65 normally work in concert to antagonize the
cellular antiviral response.
In light of the role that pp65 plays in suppressing activation of the
IFN pathway, it is curious that pp65 exhibits only a small growth
defect in cultured fibroblasts (11). It is possible that HCMV
expresses other proteins that target downstream effects of the
IFN-induced proteins, thereby allowing it to replicate efficiently in
the presence of an activated IFN-response pathway. Alternatively,
pp65 suppression of IFN signaling may play a more significant role
in vivo, or in a different cell type. Consistent with an in vivo role,
deletion of the murine cytomegalovirus homologue, M83, leads to
attenuated replication of the mutant virus in infected animals (32).
Because NF-B DNA-binding activity was greatly enhanced
after infection with pp65 relative to infection with wild-type virus
(Fig. 4B), we propose that the ability of pp65 to inhibit antiviral gene
expression is largely mediated by blocking the activation of NF-B.
IRF1 activity also was enhanced after infection with the pp65-
deficient virus, but, because expression of IRF1 is itself IFN
responsive, it is likely that its induction is a secondary consequence
of the block rather than a primary target.
Several reports have shown that NF-B is activated by infection
with wild-type HCMV, and NF-B has been proposed to play an
accessory role in activation of viral gene expression (16, 17, 33).
Indeed, the HCMV major immediate–early promoter contains
multiple NF-B binding sites (34). Furthermore, the induction of
NFB has been proposed to block apoptosis in herpes simplex type
1-infected cells (35), and it could conceivably do the same in
HCMV-infected cells. Why would HCMV antagonize a cellular
factor if it promotes viral replication? Possibly, the virus induces an
intermediate level of NF-B activity, a level that is sufficient to
promote viral replication, but does not fully induce antiviral genes.
Our observation that only a subset of IFN-responsive genes are
induced after mutation of pp65 (Table 1) is consistent with a model
in which pp65 acts by targeting NF-B. Many IFN-responsive genes
are regulated by a combination of several different factors including
NF-B (36). It is likely that the genes showing the greatest differ-
ence in expression level between wild-type HCMV and pp65 are
the genes whose expression is most dependent on NF-B. The
mechanism by which pp65 inhibits the full activation of NF-B is
unclear. It could act indirectly to prevent its release from IB in the
cytoplasm, or it could promote the degradation of NF-B or its
removal from the nucleus.
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